Melanoma overdiagnosis: why it matters and what can be done about it

Affiliations

¹ Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Edward Ford Building (A27), Camperdown, Sydney, NSW, 2006, Australia.
² Department of Dermatology, Erasmus MC Cancer Institute, Doctor Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands.

Comment

Katy J L Bell et al. Br J Dermatol. 2022 Oct.

. 2022 Oct;187(4):459-460.

doi: 10.1111/bjd.21750. Epub 2022 Aug 5.

¹ Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Edward Ford Building (A27), Camperdown, Sydney, NSW, 2006, Australia.
² Department of Dermatology, Erasmus MC Cancer Institute, Doctor Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands.

Abstract

Linked Article: Whiteman et al. Br J Dermatol 2022; 187:515–522.

The effect of screening on melanoma incidence and biopsy rates.
Whiteman DC, Olsen CM, MacGregor S, Law MH, Thompson B, Dusingize JC, Green AC, Neale RE, Pandeya N; QSkin Study. Whiteman DC, et al. Br J Dermatol. 2022 Oct;187(4):515-522. doi: 10.1111/bjd.21649. Epub 2022 Jun 28. Br J Dermatol. 2022. PMID: 35531668 Free PMC article.

1. Whiteman DC, Olsen CM, MacGregor S et al. The effect of screening on melanoma incidence and biopsy rates. Br J Dermatol 2022; 187:515–22. - PMC - PubMed
1. Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med 2021; 384: 72–9. - PubMed
1. Semsarian CR, Ma T, Nickel B et al. Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus? Br J Dermatol 2022; 186:1030–2. - PMC - PubMed
1. Bell KJL, Mehta Y, Turner RM et al. Fear of new or recurrent melanoma after treatment for localised melanoma. Psychooncology 2017; 26:1784–91. - PubMed
1. Ackermann DM, Dieng M, Medcalf E et al. Assessing the Potential for Patient‐led Surveillance After Treatment of Localized Melanoma (MEL‐SELF): a pilot randomized clinical trial. JAMA Dermatol 2022; 158: 33–42. - PMC - PubMed